101 related articles for article (PubMed ID: 15243112)
1. Differences in clinical manifestation of Streptococcus pneumoniae infection are not correlated with in vitro production and release of the virulence factors pneumolysin and lipoteichoic and teichoic acids.
Spreer A; Lis A; Gerber J; Reinert RR; Eiffert H; Nau R
J Clin Microbiol; 2004 Jul; 42(7):3342-5. PubMed ID: 15243112
[TBL] [Abstract][Full Text] [Related]
2. Presence of nonhemolytic pneumolysin in serotypes of Streptococcus pneumoniae associated with disease outbreaks.
Jefferies JM; Johnston CH; Kirkham LA; Cowan GJ; Ross KS; Smith A; Clarke SC; Brueggemann AB; George RC; Pichon B; Pluschke G; Pfluger V; Mitchell TJ
J Infect Dis; 2007 Sep; 196(6):936-44. PubMed ID: 17703426
[TBL] [Abstract][Full Text] [Related]
3. Detection of pneumolysin and autolysin genes among antibiotic resistant Streptococcus pneumoniae in invasive infections.
Sourav S; Patricia A; Sharma S; Kanungo R; Jayachandran S; Prashanth K
Indian J Med Microbiol; 2010; 28(1):34-9. PubMed ID: 20061761
[TBL] [Abstract][Full Text] [Related]
4. Influence of subinhibitory concentrations of protein-synthesis-inhibiting antibiotics on production and release of the pneumococcal virulence factor pneumolysin in vitro.
Spreer A; von Ruden C; Mitchell TJ; Eiffert H; Nau R
Chemotherapy; 2007; 53(5):327-31. PubMed ID: 17728540
[TBL] [Abstract][Full Text] [Related]
5. Differences in virulence for mice among Streptococcus pneumoniae strains of capsular types 2, 3, 4, 5, and 6 are not attributable to differences in pneumolysin production.
Benton KA; Paton JC; Briles DE
Infect Immun; 1997 Apr; 65(4):1237-44. PubMed ID: 9119457
[TBL] [Abstract][Full Text] [Related]
6. Protection against bacteremic pneumococcal infection by antibody to pneumolysin.
Musher DM; Phan HM; Baughn RE
J Infect Dis; 2001 Mar; 183(5):827-30. PubMed ID: 11181163
[TBL] [Abstract][Full Text] [Related]
7. Pneumococcal lipoteichoic and teichoic acid.
Fischer W
Microb Drug Resist; 1997; 3(4):309-25. PubMed ID: 9442483
[No Abstract] [Full Text] [Related]
8. Pneumolysin detection identifies atypical isolates of Streptococcus pneumoniae.
Kearns AM; Wheeler J; Freeman R; Seiders PR; Perry J; Whatmore AM; Dowson CG
J Clin Microbiol; 2000 Mar; 38(3):1309-10. PubMed ID: 10755884
[No Abstract] [Full Text] [Related]
9. Pneumolysin in pneumococcal adherence and colonization.
Rubins JB; Paddock AH; Charboneau D; Berry AM; Paton JC; Janoff EN
Microb Pathog; 1998 Dec; 25(6):337-42. PubMed ID: 9895272
[TBL] [Abstract][Full Text] [Related]
10. Human lung mast cells mediate pneumococcal cell death in response to activation by pneumolysin.
Cruse G; Fernandes VE; de Salort J; Pankhania D; Marinas MS; Brewin H; Andrew PW; Bradding P; Kadioglu A
J Immunol; 2010 Jun; 184(12):7108-15. PubMed ID: 20483738
[TBL] [Abstract][Full Text] [Related]
11. Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines.
Kirkham LA; Kerr AR; Douce GR; Paterson GK; Dilts DA; Liu DF; Mitchell TJ
Infect Immun; 2006 Jan; 74(1):586-93. PubMed ID: 16369015
[TBL] [Abstract][Full Text] [Related]
12. Membrane lipoteichoic acid is not a precursor to wall teichoic acid in pneumococci.
Briles EB; Tomasz A
J Bacteriol; 1975 Apr; 122(1):335-7. PubMed ID: 235510
[TBL] [Abstract][Full Text] [Related]
13. Physiology of lipoteichoic acids in bacteria.
Fischer W
Adv Microb Physiol; 1988; 29():233-302. PubMed ID: 3289326
[No Abstract] [Full Text] [Related]
14. The immunising effect of pneumococcal nasopharyngeal colonisation; protection against future colonisation and fatal invasive disease.
Richards L; Ferreira DM; Miyaji EN; Andrew PW; Kadioglu A
Immunobiology; 2010 Apr; 215(4):251-63. PubMed ID: 20071053
[TBL] [Abstract][Full Text] [Related]
15. Phosphocholine of pneumococcal teichoic acids: role in bacterial physiology and pneumococcal infection.
Fischer W
Res Microbiol; 2000; 151(6):421-7. PubMed ID: 10961454
[TBL] [Abstract][Full Text] [Related]
16. Antibody response to pneumolysin and to pneumococcal capsular polysaccharide in healthy individuals and Streptococcus pneumoniae infected patients.
Huo Z; Spencer O; Miles J; Johnson J; Holliman R; Sheldon J; Riches P
Vaccine; 2004 Mar; 22(9-10):1157-61. PubMed ID: 15003643
[TBL] [Abstract][Full Text] [Related]
17. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae.
Briles DE; Hollingshead SK; Paton JC; Ades EW; Novak L; van Ginkel FW; Benjamin WH
J Infect Dis; 2003 Aug; 188(3):339-48. PubMed ID: 12870114
[TBL] [Abstract][Full Text] [Related]
18. Implication of pneumolysin as a virulence factor in Streptococcus pneumoniae endophthalmitis.
Ng EW; Samiy N; Rubins JB; Cousins FV; Ruoff KL; Baker AS; D'Amico DJ
Retina; 1997; 17(6):521-9. PubMed ID: 9428015
[TBL] [Abstract][Full Text] [Related]
19. Amino acid changes affecting the activity of pneumolysin alter the behaviour of pneumococci in pneumonia.
Alexander JE; Berry AM; Paton JC; Rubins JB; Andrew PW; Mitchell TJ
Microb Pathog; 1998 Mar; 24(3):167-74. PubMed ID: 9514638
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor 2 contributes to antibacterial defence against pneumolysin-deficient pneumococci.
Dessing MC; Florquin S; Paton JC; van der Poll T
Cell Microbiol; 2008 Jan; 10(1):237-46. PubMed ID: 17711480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
